Skip to main content

Pediatric diabetes


Browse the latest news, expert commentary, and educational content on pediatric diabetes.


Monoclonal antibody model

10-23-2023 | Type 1 diabetes | News

Teplizumab may PROTECT β-cell function in youth with newly diagnosed type 1 diabetes

Early treatment with the anti-CD3 monoclonal antibody teplizumab may help to preserve β-cell function in children and adolescents with newly diagnosed type 1 diabetes, results of the phase 3 PROTECT study show.

04-05-2023 | Flash glucose monitoring | News

Reduced acute complications for young people using CGM

Data from the DPV cohort show a reduced risk for severe hypoglycemia and diabetic ketoacidosis among children and young people with type 1 diabetes using continuous glucose monitoring rather than self-monitored blood glucose.

03-30-2023 | Artificial pancreas systems | News

Virtual closed-loop initiation success in very young children

The Tandem Control-IQ system delivers improved glucose control versus standard care in children with type 1 diabetes aged between 2 and 6 years and can be initiated virtually, report researchers.

03-21-2023 | Diabetes prevention | News

Verapamil promising for preserving beta-cell function in children

Two linked randomized trials published in JAMA support a role for verapamil, but not for intensive glycemic control, to slow C-peptide decline in children with newly diagnosed type 1 diabetes.

02-03-2023 | Empagliflozin | News

DINAMO: Empagliflozin shows promise for young people with type 2 diabetes

Empagliflozin, but not linagliptin, provides “clinically relevant” improvements in glycemic control versus placebo in children and adolescents with type 2 diabetes, report the DINAMO investigators.

01-26-2023 | Screening | News

Age 10 years is optimal type 1 diabetes screening point for adolescents

“Almost no one” who is islet autoantibody negative at age 10 years despite a high familial risk for type 1 diabetes will develop clinical diabetes by the age of 18, report researchers.

01-09-2023 | Semaglutide | News

FDA approves high-dose semaglutide for adolescents with obesity

Read more about this decision here

12-19-2022 | Early onset | News

Global type 2 diabetes burden increasing in adolescents and young adults

The incidence and burden of type 2 diabetes in young people aged 15–39 years are increasing worldwide, show data from the Global Burden of Disease Study.

11-30-2022 | Artificial pancreas systems | News

Real-world data show reduced diabetes burden in young closed-loop users

Real-world use of hybrid closed-loop insulin delivery is associated with improved glycemic control and sleep quality, as well as reduced fear of hypoglycemia in children and young people with type 1 diabetes, shows a UK study.

11-22-2022 | Dulaglutide | News

FDA clears dulaglutide for adolescents

Click through to read more on this announcement

11-18-2022 | Teplizumab | News

FDA clearance for teplizumab to slow type 1 diabetes onset

Click through to read more on this announcement

11-16-2022 | Epidemiology | News

Modeling suggests substantial underdiagnosis of childhood type 1 diabetes

Nearly half of all cases of type 1 diabetes occurring annually in children and adolescents may go undiagnosed, especially in low- and middle-income countries, show the results of a modeling study.

11-02-2022 | Semaglutide | News

STEP TEENS: High-dose semaglutide weight loss benefits shown in adolescents

Semaglutide at a dose of 2.4 mg/week results in substantial weight loss among adolescents with obesity, show the results of the STEP TEENS trial.

10-27-2022 | Screening | News

IAA screening may improve classification of autoimmune diabetes in children

Testing for autoantibodies to endogenous insulin in addition to regular autoantibody screening can increase the proportion of children with an autoimmune classification for newly diagnosed type 1 diabetes, UK research suggests.